- Economy
- Education And Career
- Companies & Markets
- Gadgets & Technology
- After Hours
- Healthcare
- Banking & Finance
- Entrepreneurship
- Energy & Infra
- Case Study
- Video
- More
- Sustainability
- Web Exclusive
- Opinion
- Luxury
- Legal
- Property Review
- Cloud
- Blockchain
- Workplace
- Collaboration
- Developer
- Digital India
- Infrastructure
- Work Life Balance
- Test category by sumit
- Sports
- National
- World
- Entertainment
- Lifestyle
- Science
- Health
- Tech
Latest Articles in Intranasal Covid Vaccine
Union Health Minister Launches First Intranasal Covid Vaccine
A rollout of iNCOVACC is expected to begin in private hospitals that have placed advance orders
Read More
Bharat Biotech's Intranasal Vaccine Priced At Rs 325 Per Dose In Govt Setups, Rs 800 For Private Settings
Earlier this month, Bharat Biotech received approval from the Central Drugs Standard Control Organization (CDSCO) for the use of heterologous booster doses of iNCOVACC. The booster dose is now available on CoWin, and priced at Rs 800 for private markets and priced at Rs 325 for supplies to Govt of India and State Governments
Read More
Study on Animals Shows Intranasally Delivered Sputnik V Vaccine Give Robust Immune Response Against Covid
The vaccine induced a robust (no less than 180 days) systemic and local immune response. Study’s findings demonstrate that in the mouse model, intranasal and intramuscular administration of Sputnik V vaccine elicits comparable magnitude of central antigen-specific immunity, while only intranasal vaccination forms humoral and cell-mediated response in lungs
Read More
Bharat Biotech's Intranasal Covid Vaccine Completes Phase III Trials
Product development related to pre-clinical safety evaluation, large-scale manufacturing scale-up, formulation, and delivery device development, including human clinical trials, was conducted by Bharat Biotech. The Centre partially funded product development and clinical trials through the Department of Biotechnology's, COVID Suraksha programme
Read More
Bharat Biotech Hopeful To Get Regulator's Nod For Intranasal Covid Vaccine
The Drug Controller General of India gave its nod to conduct clinical trials for BBIL's intranasal vaccine as booster dose. Separately, the DCGI also granted permission to the firm to conduct phase-3 clinical trial to compare the immunogenecity and safety of BBV-154 (intranasal) with Covaxin. This trial has been permitted to be conducted at nine sites
Read More
Bharat Biotech Expects To Get A Nod For Its Intranasal Covid-19 Vaccine By Aug
The Drug Controller General approved the official trials on the intranasal Covid-19 vaccine and so the company is hopeful of getting regulatory licenses in August.
Read More
Intranasal Covid Vaccines Critical To Protect People Against Emerging Variants: Study
Researchers at the University of Virginia (UVA) in the US noted that the widely available COVID-19 vaccinations
Read More
Bharat Biotech To Initiate Phase I Trials Of Intranasal Covid Vaccine
Bharat Biotech is also developing Covaxin, which is a vaccine against the infectious Corona Virus and is undergoing phase three trials currently.
Read More